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new antigens deriving from ‑lloyl and ‑llanyl, major and minor determinants, respectively, were 
produced for β-lactam antibiotics cefuroxime, cefotaxime, ceftriaxone, meropenem and aztreonam. 
Twenty β-lactam antigens were produced using human serum albumin and histone H1 as carrier 
proteins. Antigens were tested by multiplex in vitro immunoassays and evaluated based on the 
detection of specific IgG and IgE in the serum samples. Both major and minor determinants were 
appropriate antigens for detecting specific anti-β-lactam IgG in immunised rabbit sera. In a cohort 
of 37 allergic patients, we observed that only the minor determinants (-llanyl antigens) were 
suitable for determining specific anti-β-lactam IgE antibodies with high sensitivity (< 0.01 IU/mL; 
24 ng/L) and specificity (100%). These findings reveal that not only the haptenisation of β-lactam 
antibiotics renders improved molecular recognition events when the 4-member β-lactam ring remains 
unmodified, but also may contribute to develop promising minor antigens suitable for detecting 
specific IgE-mediated allergic reactions. This will facilitate the development of sensitive and selective 
multiplexed in vitro tests for drug-allergy diagnoses to antibiotics cephalosporin, carbapenem and 
monobactam.
Between 2000 and 2015, antibiotic consumption, expressed in defined daily doses (DDD), increased 65% 
(21.1–34.8 billion DDDs) and its rate rose 39% (11.3–15.7 DDDs per 1000 inhabitants/day). This increase was 
driven by low- and middle-income countries, where rising consumption has been correlated with gross domestic 
product per capita  growth1. In fact β-lactams (BLCs) are the most widely used antibiotics for treating bacterial 
infections and, consequently, the most frequent cause of allergic  reactions2–5. They represent one of the world’s 
major biotechnology markets with annual sales of around $15 billion, and make up around 65% of the total 
antibiotics market (world’s antibiotic sales of 3 × 107 kg/year of a total 5 × 107 kg/year produced worldwide)6. For 
many years, the most commonly prescribed and studied BLCs were  penicillins4,7,8 like benzylpenicillin (PG), 
amoxicillin (AMX) or ampicillin (AMP). Due to the increased allergies related to penicillins, antibiotic research 
rapidly led to the discovery and use of several other BLC  families9. Indeed the global antibiotic consumption rate 
of cephalosporins, carbapenems and monobactams were 135.45, 11.26 and 6.23 DDDs, respectively, between 
2016 and  201810. In fact the consumption of all these other BLCs in 2018 was 2.0 DDDs per 1000 inhabitants 
per day, which accounts for around 11% of the total European  intake11.
The chemical structure differences among BLC antibiotics promote the allergenic recognition of a broad spec-
trum of immune system specificities and may therefore help to provoke adverse reactions. BLCs generate -lloyl 
determinants after β-lactam ring opening under physiologic conditions. According to the bibliography, this -lloyl 
determinant is considered to be the ‘major’ determinant for penicillins because it is responsible for almost 95% 
of all allergic reactions to  penicillins12. The other determinants are classified as ‘minor’ or -llanyl determinants, 
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and are associated with causing anaphylaxis in immediate immunoglobulin E (IgE)-mediated reactions in 95% of 
 cases13,14, but the explanation for the direct involvement of these determinants in provoking immediate hypersen-
sitivity reactions still remains  unclear15. To date, many studies have focused on major  determinants16. However, 
BLC allergic reactions caused by minor determinants have been considered extremely important in penicillin 
allergies; e.g., in skin tests for diagnosing β-lactam  allergy17, and have been associated with specific systemic 
 anaphylaxis18. For this reason, it is necessary to systematically and clinically study the relevance and relative 
importance of these -llanyl derivatives as a new range of ‘minor’ determinants for β-lactam  allergy13. Several 
prospective studies are found in the literature that have evaluated the use of  cephalosporins4,5,19,20,  carbapenems21 
or monobactams in patients with documented penicillin allergy who specifically require BLC treatment, but very 
few in vitro assays are available for these  studies3. In any case, many patients supposedly allergic to a BLC, or at 
least present allergic episode to them, are usually classified as allergic to a drug with no further  investigation22 
or are not treated with BLCs because patients might be affected by them and at risk for anaphylaxis. The use of 
other antibiotics may contribute to the development of multiple drug-resistant bacteria, the emergence of other 
potentially dangerous side effects and a lead-in of higher healthcare  costs2. Whatever the case, those patients 
self-reporting a penicillin allergy can be safely tested for the presence of a true allergy, normally by allergy 
diagnosis tests.
Allergy diagnoses must include a detailed clinical history, physical examination and in vivo tests (skin and/
or drug provocation tests). However, these tests pose life-threatening risks and can entail false-positive skin test 
 results23. Currently, the gold standard in vitro test is based on ImmunoCap technology, but it is available only 
for five BLCs: PG, phenoxymethyl penicillin, AMP, AMX, cefaclor. Therefore, good antigenic determinants are 
lacking to develop accurate immunoassays with the potential for determining specific IgE to other BLCs in order 
to cover other subfamilies of BLCs to improve clinical diagnoses. A good diagnosis that relies on both in vivo 
and in vitro tests could allow a significant delabelling of the reported BLC allergy, and the majority of patients 
tolerate BLCs without  incidents24. Furthermore, effective immunoassays for allergy diagnosis rely on the selec-
tion of appropriate haptens and metabolites to elicit an immune response. An examination of the specificities 
of BLC-reactive IgE antibodies in sera revealed a heterogeneous group of allergenic determinants, probably 
because the authors did not take into account the fine structural heterogeneity of the allergenic determinants 
of the complete range of  BLCs25. When designing determinants, it is important to retain the functional groups 
that are unique to  hapten26.
In this work, the main objective was to design and produce major and minor -lloyl- and -llanyl-derived 
antigens, respectively, for cefuroxime (CFR), cefotaxime (CFO), ceftriaxone (CFT), meropenem (MRP) and 
aztreonam (AZT). Compounds were evaluated by a multiplex direct microimmunoassay developed on the Digital 
Versatile Disk (DVD) using sera from immunised rabbits, and allergic patients and controls. To the best of our 
knowledge, this is the first report of major and minor -lloyl and -llanyl antigens for these antibiotics, and this 
work demonstrates the potential for an improved serological diagnosis of IgE-mediated drug allergic reactions 
for commonly prescribed and consumed β-lactam antibiotics.
Experimental section
Chemicals, immunoreagents and buffers. Benzylpenicillin sodium salt, meropenem trihydrate, aztre-
onam, cefuroxime sodium salt, cefotaxime sodium salt, ceftriaxone disodium salt hemi(heptahydrate), N,N′-
dicyclohexylcarbodiimide (DCC), N-hydroxysuccinimide (NHS), Tween 20, human serum albumin (HSA), his-
tone from calf thymus (H1) and keyhole limpet hemocyanin (KLH) came from Sigma-Aldrich (Madrid, Spain). 
The chemical structures of the studied BLCs are shown in Fig. 1. Dichloromethane (DCM), dimethylformamide 
(DMF), hydrochloric acid 37% (HCl) and buffer salts were purchased from Scharlau (Sentmenat, Spain) and 
used without further purification. Deuterated dimethyl sulfoxide (DMSO-d6) was supplied by ACROS Organ-
ics (New Jersey, USA). The anti-human IgE monoclonal antibody was purchased from Ingenasa, S.A. (Madrid, 
Spain). The goat anti-rabbit antibody labelled with horseradish peroxidase (GAR-HRP) and the goat anti-mouse 
antibody labelled with horseradish peroxidase (GAM-HRP) were supplied by Abcam (Cambridge, UK). IgE 
human serum (3rd WHO International Standard) was bought from the National Institute for Biological Stand-
ards and Control (NIBSC, Hertfordshire, UK). The tetramethylbenzidine (TMB) substrate came from SDT 
GmbH (Baesweiler, Germany) and Coomassie Brilliant Blue R-250 staining solution was acquired from Bio-Rad 
(Madrid, Spain). Amicon Ultra 0.5 pre-concentred 10K MWCO filters and Dextran Desalting Columns, 5K 
MWCO, 5 mL were from Fisher Scientific (Madrid, Spain).
Buffers were: (I) potassium carbonate 0.5 M, pH 11.0; (II) phosphate buffer saline (PBS 1 ×, 0.008 M sodium 
phosphate dibasic, 0.002 M sodium phosphate monobasic, 0.137 M sodium chloride, 0.003 M potassium chloride, 
pH 7.4); (III) PBS-T (PBS 1 × containing 0.05% Tween 20); (IV) sodium carbonate/bicarbonate buffer 0.1 M, 
pH 9.6, as the printing buffer. All the buffers were filtered through a 0.45-μm pore size nitrocellulose membrane 
from Thermo Fisher Scientific (Madrid, Spain) before being used.
Acidification of cephalosporin salts. Firstly, cephalosporin salts were acidified as follows: a round-bot-
tomed flask was filled with a solution of the corresponding BLC salt dissolved in water. Then the solution was 
acidified with HCl 6 M followed by filtration in a vacuum. The compound was washed twice with acidified water 
and dried in a high vacuum to obtain the desired acid. The detailed procedures and data characterisation of all 
the acidified cephalosporins are shown in the online Supplementary Information (SI).
Preparation of the structural antigens. KLH was used to produce the immunogenic antigens (-lloyl 
and -llanyl), with which New Zealand white rabbits were immunised to raise specific IgG for CFT as a model of 
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cephalosporin, MRP and AZT. Two carrier proteins, HSA and H1, were employed to produce the antigens. The 
preparation was as follows:
The β-lactam-lloyl determinants were linked through the lysine residues of the carrier proteins by β-lactam 
ring opening, through the amidation between the carbonyl carbon of the β-lactam ring and the amino group 
of the lysine residues, as previously  described27 with a few modifications (Fig. 2). In short, the carrier pro-
tein (2.0 mg) dissolved in potassium carbonate 0.5 M, pH 11.0, was reacted with the corresponding BLC salt 
(22–30 μmol depending on the used protein) overnight at room temperature.
The conjugation of the β-lactam -llanyl determinants was performed following the carbodiimide  chemistry28 
(Fig. 3). For that purpose, 22–30 μmol (depending on the employed carrier protein) of the corresponding BLC 
as its free acid were reacted with 55 μmol of NHS and DCC in DMF (500 μL) for 4 h at room temperature. 
Afterwards, the mixture was centrifuged at 12,000 rpm to remove the acyl urea precipitate. Finally, 250 μL of 
the supernatant were added to 2.25 mL of the carrier protein solution (2.0 mg) in PBS 1 ×, pH 7.4, for 4 h at 
room temperature.
Instead of the chemical structure of AZT having a free carboxylic acid, it had a sulfonate moiety attached to 
the β-lactam ring (Fig. 1). For this reason, the AZT-llanyl determinant was prepared with the free carboxylic acid 
presented in its side chain following the same procedure as described for the -llanyl determinants.
Figure 1.  Chemical structures of the studied β-lactam antibiotics. ChemDraw Professional, Version 17.0.0.206 
(121) https ://www.perki nelme r.com/es/produ ct/chemd raw-profe ssion al-chemd rawpr o.
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The HSA and H1 -lloyl and -llanyl determinants were purified by gel filtration chromatography using Ami-
con Ultra 0.5 pre-concentred 10 K filters and PBS 1X, pH 7.4, as the elution buffer. The KLH -lloyl and -llanyl 
determinants were purified by size exclusion chromatography on dextran desalting columns using PBS 1 ×, pH 
7.4, as an elution buffer.
All the determinants were diluted to 1.0 mg/mL and stored at – 20 °C until used. The concentration of the 
determinants was established by the Bradford protein  assay29. The β-lactam/carrier protein molar ratio for the 
HSA determinants was established by MS-MALDI-TOF30. Histone H1 is an isolated lysine-rich fraction of mainly 
subfraction f1, with the other subfractions still present. The H1 antigens could not be analysed by MS-MALDI-
TOF. However, antigens HSA and H1 were prepared following the same experimental procedure and according 
to the formation of the major or minor determinants. As both proteins presented approximately 60 free lysine 
residues, the molar ratios of antigens H1 were estimated to be the same as those obtained for the respective HSA 
antigens. The KLH determinants were difficult to characterise because of the protein’s high molecular weight. 
The selectivity of the raised rabbit IgGs was tested during the immunisation by the dot blot  technique31 and the 
conjugation was considered positive when the sera obtained from the immunised rabbit specifically recognised 
the corresponding antigen.
Assay protocol to evaluate antigens. The assays consisted in detecting specific IgG (Fig. 4a, assay I) and 
IgE (Fig. 4b, assay II) on standard DVDs (CD Rohling-up GmbH, Saarbrücken, Germany). To this end, determi-
nants (40 µg/mL) and controls (negative and positive), prepared in printing buffer, were spotted in a microarray 
format (20 arrays per disk of 5 × 4 spots) by dispensing 25 nL of each one using a non-contact printing device 
(AD 1500 BioDot, Inc., Irvine, CA, USA). Spots were 500 μm in diameter with a centre-to-centre distance of 
1.0 mm. In each microarray (Fig. 5), the spots for the produced determinants (two replicates, position 2–9) and 
the negative (HSA, position 1) and positive (rabbit IgG or human IgE, position 10) controls were included. After 
printing, the DVD was incubated for 16 h at 37 °C.
To detect specific IgG against CFT, MRP and AZT, different dilutions (1/250–1/16,000) of the rabbit sera 
and control (PBS-T) (25 µL per sample) were added to each array and incubated for 15 min. Then the DVD was 
washed with PBS-T and water before adding 25 µL of polyclonal secondary antibody GAR-HRP in PBS-T buffer 
Figure 3.  Conjugation of protein CFT -llanyl determinant.
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(dilution 1/400) for 15 min, followed by the washing step. To detect specific IgE, 25 µL of the sample (allergic 
patients and controls) was added to each array and incubated for 30 min. After washing, 25 µL of the mAb-IgE 
in PBS-T buffer (1 µg/mL) were added and incubated for 15 min. After washing like before, 25 µL of a 1/100 
dilution of GAM-HRP were added for 15 min. Finally, an immunoreaction was run in both immunoassays by 
homogeneously dispensing 1.0 mL of TMB over the entire disc surface. The reaction was stopped by washing the 
disk with water after 15 min. Signals were read by a modified DVD drive and data were analysed as previously 
 described32,33. All the experiments were repeated 3 times.
The affinity of the specific IgGs to CFT, MRP and AZT towardsthe antigens was calculated by measuring the 
apparent affinity constant  (Kdapp) in the saturation assays.  Kdapp represents the apparent equilibrium dissocia-
tion constant between specific IgG and the corresponding antigenic determinant, and is related to the in vitro 
concentration (expressed as the dilution factor) of the specific IgG antibodies that reached half the maximum 
signal in the saturation assay. Binding curves were fitted by the SigmaPlot 11 software.
The BLC-specific IgE levels expressed as units of specific IgE (IU/mL) were determined by the 3rd WHO 
standard for total serum IgE determinations, which involves heterologous interpolation as a calibration scheme. 
The calibration curve was built by performing a sandwich immunoassay where the 3rd WHO International 
Standard was used as a calibrator and  Omalizumab34 as the capture antibody. All the other immunoreagents 
were the same as those used for determining specific IgE (assay II). The standard data points, signal versus semi-
log concentration, were the mean of 10 curves performed on different disks on distinct days. A four-parameter 
logistic (4PL) curve was fitted (Supp. Fig. S1) using the SigmaPlot 11 software. The specific IgE concentrations 
were calculated from the calibration curve for the total IgE.
Serum samples. The study of the reactivity of the prepared determinants to the sera from the allergic 
patients included those patients (I) who had been diagnosed with an immediate allergic reaction to a BLC 
by prick test;s (II) whose culprit drug was one BLC (e.g. antibiotics amoxicillin, augmentin, benzylpenicillin, 
cefuroxime and ceftriaxone); (III) with the total IgE (tIgE) values between 100 and 400 IU/mL (clinically con-
sidered the normal range for total IgE in a healthy  population35). The clinical characteristics of the 37 patients 
included in this study are shown in Table 1. Thirty-seven subjects with negative skin tests to BLCs and good 
tolerance to them were used as controls. Their clinical characteristics are shown in Table  S1. All the serum 
samples were kindly provided by the Hospital Universitari i Politènic La Fe in Valencia, Spain. All participants 
were enrolled after giving written informed consent according to protocols approved by the ethics review board 
at La Fe University Hospital (registry no. COBIOPHAD). The procedures followed were in accordance with the 
Helsinki Declaration of 1975 as revised in 2008. The patients were diagnosed following the procedure described 
in the European Network of Drug Allergy (ENDA) protocol based on skin testing, in vitro tests or drug provoca-
tion test, whenever necessary.
Results and discussion
Production of β-lactam antigens. Firstly, acidification of cephalosporin salt (CFR, CFO and CFT) was 
attempted to obtain the corresponding carboxylic acid. The reaction proceeded easily with a high yield (ca. 90%). 
The purity of the acidified BLC was high (see the NMR spectra in the Supplementary Information). The produc-
tion of antigens relied on the conjugation of the acidified BLC (CFR, CFO, CFT, MRP and AZT) to the carrier 
 proteins36,37. In this study, human serum albumin and histone H1 were used, and both presented approximately 
60 free lysine residues to approach two different conjugation routes in order to obtain the corresponding major 
and minor determinants for each β-lactam antibiotic. The initial molar ratio (β-lactam/carrier protein) was set at 
1000/1 and 240/1 for HSA and H1, respectively, to ensure the conjugation of antibiotics. No elucidation method 
was followed for the characterisation of the determinants. However, according to the MS-MALDI-TOF results 
(see the online Supplementary MS-MALDI-TOF spectra), the molar ratio of the HSA antigens ranged from 1 to 
Figure 5.  (a) Layout of the multiplexed microarray. Position 1: HSA, negative control, C(−); and Position 10: 
rIgG or hIgE, positive control, C(+); (b) Image of an array on the DVD after immunoassay I with α-IgG to 
CFT, dilution factor 1/1,000 (Position P1: HSA, negative control; P2: CFT-HSA-llanyl determinant; P3: CFT-
HSA-lloyl determinant; P4: CFT-H1-lloyl determinant; P5: CFR-HSA-llanyl determinant; P6: CFO-H1-llanyl 
determinant; P7: CFR-H1-lloyl determinant; P8: CFR-H1-llanyl determinant; P9: CFO-H1-llanyl determinant; 
P10: rIgG); (c) Representative result of the array with specific determinants and controls printed on the DVD 
after immunoassay II with patient 002 (determinants in the same positions as in (b), except for P10: hIgE).
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8. In particular, the molar ratios of both the aztreonam and ceftriaxone major and minor antigens were similar, 
whereas the molar ratios were 1 and 8, respectively, for the meropenem antigens. In general, the conjugation 
yield was very low for the HSA antigens (< 0.8%). This could be due to the protecting-group-free production of 
the -llanyl antigens. Most of the studied BLCs bear a primary amine group in their R substituent, which could 
compete with that amino from Lys to form some kind of oligomers of β-lactam by amidation.
Evaluation of antigens. The antigens were firstly evaluated as a proof of concept using sera raised to 
both the -loyl and -llanyl antigens for CFT, MRP and AZT. As observed in Supplementary Figs. S2–S4, the sera 
obtained from the immunised rabbit with the -lloyl-based determinants specifically recognised the correspond-
ing antigen in the dot-blot assay. Conversely, this was not the case with the -llanyl determinants, which showed 
no specific recognition. For instance, as seen in online Supplementary Fig. S4, the AZT sera obtained from the 
immunised rabbit with the -lloyl-based determinant specifically recognised both the -lloyl and -llanyl determi-
nant antigens at a dilution factor of 1/100 (v/v), but only recognised the AZT -lloyl antigen when the dilution 
factor was 1/500 (v/v). However, the AZT sera obtained with the -llanyl determinant did not recognise any 
determinant at any of the studied sera dilutions.
Table 1.  Clinical characteristics of the cohort of allergic patients. The terms immediate and delayed refer to 
an allergic reaction provoked by re-exposure to a specific allergen and to late-phase allergic reactions that 
generally occur between 2 and 6 h after exposure to a specific allergen, respectively. F female, M male, NR not 
reported in the clinical history.
Patient number Gender Age (years) Culprit Drug Clinical manifestation Route Timing
001 M 68 Augmentin Anaphylaxis Parenteral Immediate
002 F 46 Cefuroxime Anaphylaxis Oral Immediate
003 F 53 Cefuroxime Cutaneous Oral Delayed
004 M 49 Augmentin Cutaneous Oral Delayed
005 M 80 Augmentin Anaphylaxis Parenteral Immediate
006 F 37 Cefuroxime Cutaneous Oral Immediate
007 M 40 Augmentin Cutaneous Oral Immediate
008 F 24 Amoxicillin Cutaneous Oral Immediate
009 M 27 Ceftriaxone Cutaneous Parenteral Immediate
010 F 68 Augmentin Anaphylaxis Parenteral Immediate
011 F 49 Augmentin Anaphylaxis NR Immediate
012 F 52 Augmentin Anaphylaxis Oral Immediate
013 M 61 Augmentin Cutaneous Oral Delayed
014 F 34 Cefuroxime Anaphylaxis Oral Immediate
015 M 54 Amoxicillin Anaphylaxis Oral Immediate
016 M 10 Amoxicillin Unspecific Oral NR
017 F 41 Amoxicillin Cutaneous Oral Immediate
018 M 45 Augmentin Cutaneous Oral Delayed
019 F 53 Augmentin Cutaneous Oral Immediate
020 M 39 Amoxicillin Cutaneous Oral NR
021 F 56 Augmentin Cutaneous Oral Immediate
022 F 68 Amoxicillin Unspecific Oral Immediate
023 M 40 Penicillin G Cutaneous NR Delayed
024 M 53 Augmentin Anaphylaxis Oral Immediate
025 F 49 Ceftriaxone Anaphylaxis Parenteral Immediate
026 F 53 Augmentin Cutaneous Oral Immediate
027 M 35 Amoxicillin Anaphylaxis Oral Immediate
028 F 36 Augmentin Cutaneous Oral Immediate
029 F 54 Augmentin Cutaneous Oral NR
030 F 46 Augmentin Anaphylaxis Oral Immediate
031 F 71 Augmentin Cutaneous Oral Immediate
032 F 32 Cefuroxime Anaphylaxis Oral NR
033 F 55 Cefuroxime Cutaneous Oral Delayed
034 F 39 Cefuroxime Cutaneous Oral Delayed
035 M 46 Augmentin Anaphylaxis Oral Immediate
036 F 80 Cefuroxime Anaphylaxis NR Immediate
037 F 72 Cefuroxime Cutaneous NR Immediate
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In order to evaluate the effect of the conjugation on assay sensitivity, each -loyl and -llanyl antigen was 
screened by a direct multiplex immunoassay with the -lloyl immunised sera to CFT, MRP and AZT. The tested 
sera dilutions were 1/250, 1/1000, 1/4000 and 1/16,000, while PBS-T was used as a blank. The obtained results 
are plotted in Figs. 6 and 7 for the -lloyl and -llanyl determinants, respectively. The values represented the mean 
of the signals (n = 3) obtained in each assay, together with the standard deviation (SD) expressed as error bars. 
As shown in the figures, the signals corresponding to the positive control (rIgG) were around 15,000 a.u. (± 8%) 
for all studied sera with no recognition observed for HSA (< 500 a.u) used as a negative. The dilution of the dif-
ferent sera allowed immunoassay sensitivity to be estimated. As we can see in Fig. 7b, using sera raised to MRP 
(α-IgG-MRP) detected the meropenem -llanyl antigen up to the 1/16,000 dilution, and gave a signal value of 
1500 a.u, which corresponded to the limit of detection.
When focusing on the 1/1000 dilution, the response and cross-reactivity between the determinants for the 
different rabbit sera were compared. As we can see in Fig. 6, the -lloyl determinants for cephalosporin (CFR, 
CFO, CFT) were specifically identified mostly by the serum raised for CFT and no cross-reactivity was observed 
for AZT and MRP. A similar pattern was detected when using the AZT determinants and the serum raised for 
it. Indeed as expected, no other produced determinants were recognised, which indicates that recognition was 
specific for monobactams. Conversely, the MRP-derived determinants were recognised mostly by the corre-
sponding serum, but values were similar to those obtained for the cephalosporin antigens, which suggests than 
the selectivity of the serum raised in rabbit was not high.
As far as cross-reactivity was concerned, there was evidence for different patterns with the case -llanyl deter-
minants (Fig. 7), depending on the used carrier protein. As we can see, the serum raised for CFT mostly detected 
the antigens produced for CFO and no cross-reactivity to AZT and MRP was identified. However, the results 
were the opposite for CFR due to the poor recognition of these determinants in any studied immunisation sera. 
With CFT, the serum raised for it actually detected the HSA-antigen and cross-reactivity against other sera. In 
general, the sera increased for MRP and AZT detected the -llanyl MRP and AZT antigens, respectively, with no 
cross-reactivity to other BLCs, although AZT responses were higher than those observed with MRP.
In order to study the affinity of the structural determinants to the serum raised for the different β-lactam 
families, the binding values were analysed. The results are provided in online Supplementary Figs. S5, S6. The 
affinity values (as  Kdapp and coefficient of determination,  R2) for all the rabbit IgG antibodies to each antigenic 
determinant are shown in online Supplementary Tables S2, S3. The  Kdapp values ranged from  10–4 to  10–2 (dilu-
tion factors from ~ 1/1000 to ~ 1/20), whereas  R2 ranged between 0.9605 and 0.9994 and 0.6111 and 0.9984 for 
the -lloyl and -llanyl determinants, respectively.
Figure 6.  Signals obtained for the -lloyl determinants with polyclonal rabbit IgG. Dilution factors: 1/1000, 
1/4000 and 1/16,000). (a) HSA determinants; (b) H1 determinants.
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It can be concluded that the HSA -lloyl determinants for CFR and AZT showed the best affinity (higher dilu-
tion) to the sera raised against CFT and AZT with  Kdapp values corresponding to a dilution factor of 1/1011 and 
1/5587, respectively. However, the H1-lloyl determinants for CFT and CFO showed the best recognition to the 
sera raised against ceftriaxone at dilution factors of 1/1157 and 1/2271, respectively.
For the HSA -llanyl determinants, AZT showed the best affinity to the sera raised against it with a  Kdapp value 
corresponding to a dilution factor of 1/2228. However, the H1 -llanyl CFT and MRP determinants indicated the 
best recognition to the sera raised against them with  Kdapp values corresponding to dilution factors of 1/2168 
and 1/1437, respectively.
Even though some determinants had an affinity to serum, this did not necessarily mean that they gave a good 
 response38; e.g., this is the case with H1 -llanyl antigens CFT and CFO to the sera raised against AZT. It was 
generally concluded that the prepared major and minor determinants were selective to the recognised specific 
IgGs, with significant differences between the employed carrier proteins.
Evaluation of the structural determinants with human serum samples. A cohort of 74 subjects 
was studied, of whom 37 positively developed an immediate reaction to BLC. According to the clinical data 
available for the allergic patients, 14 were men and 23 were women aged 10 and 80 years. The most frequent 
culprit drug was augmentin, a combination of AMX and potassium clavulanate (12 subjects), followed by CFR 
(9), AMX (7), CFT (2) and PG in one subject (Table 1).
The results of the prick test and the multiplex immunoassay are described in Table 2. It is worth mentioning 
that all the -lloyl and HSA -llanyl determinants did not render any positive results, with values below the LOD 
(< 0.01 IU/mL). Only the values given by the H1 -llanyl determinants are included in Table 2.
Firstly, it is important to highlight the lack of clinical information available for skin prick-tests for most of 
the studied antibiotics. Skin tests were performed only for CFR, and sometimes for CFT. In order to assess tests’ 
clinical sensitivity and selectivity, a gold standard is needed, defined as the diagnostic method that can discrimi-
nate patients with an allergic reaction to BLCs from those without one. It is difficult to calculate the sensitivity of 
skin tests because drug provocation tests cannot be performed as a gold standard to classify subjects as allergic 
or not allergic because of the high risk they  entail39.
The skin test results showed that 6 of the 33 patients for CFR (18%), 3 of the 19 for CFT (29%) and 0 of the 
2 for CFO were positive. As far as MRP and AZT were concerned, only 2 and 1 of 7 and 3 patients were skin-
tested, which corresponded to 29% and 33%, respectively. It is noteworthy that the skin-tested patients to CFO, 
Figure 7.  Signals obtained for the -llanyl determinants with polyclonal rabbit IgG. Dilution factors: 1/1000, 
1/4000 and 1/16,000). (a) HSA determinants; (b) H1 determinants.
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MRP and AZT obtained low percentage values (in terms of being positive to skin tests versus all the skin-tested 
patients), which must not be considered a general statement.
In order to determine the LOD and BLC-specific IgE levels, a sandwich immunoassay for total serum IgE 
determinations was performed as a calibration scheme. As the LOD of the multiplex immunoassay was 0.01 IU/
mL (online Suppl. Fig. S2), which corresponded to 24 ng/L of specific IgE, we chose this LOD as the cut-off 
threshold for evaluation purposes. When the determinants with the sera of the 37 recruited patients were evalu-
ated, 13 for CFR (35%), 6 for CFT (16%), 19 for CFO (51%), 18 for MRP (49%) and 1 for AZT (3%) were positive. 
The mean IgE values ± SD of the studied BLCs were 0.27 ± 0.77, 0.02 ± 0.01, 0.05 ± 0.05, 0.23 ± 0.46 and 0.05 ± 0 IU/
mL to CFR, CFT, CFO, MRP and AZT, respectively. All the 37 control patients recruited in this study tested nega-
tive. Finally, no correlation was found between the total IgE levels from patients and the BLC-specific IgE levels.
Table 2.  Results of analysing the human serum samples by in vivo (prick test) and in vitro (multiplex 
DVD assay) tests. MDM minor determinants mixture (benzylpenicillin, sodium benzylpenicilloate and 
benzylpenicilloic acid), PPL penicillin major determinant (benzylpenicilloyl poly-l-lysine), PG benzylpenicillin, 
AMP ampicillin, AMX amoxicillin, CFR cefuroxime, CFT ceftriaxone, CFO cefotaxime, MRP meropenem, AZT 
aztreonam. Immunoassay values are the mean of three replicates. Relative standard deviation (RSD) ranged 
from 4 to 13%. a P Positive, N Negative, NR Not reported in the clinical history. b Multiplex-DVD assay using 
the H1–llanyl determinants. c IU/mL = 2.4 ng/mL. d Augmentin is a combination of amoxicillin and potassium 
clavulanate. e < LOD Value below the limit of detection (LOD).





c) MDM PPL PG AMP AMX CFR CFT CFO MRP AZT CFR CFT CFO MRP AZT
001 Augmentind 265 N N N N P P N NR NR N <LODe <LOD <LOD <LOD <LOD
002 Cefuroxime 129 NR NR NR NR P NR P NR P NR 0.37 0.01 0.02 <LOD <LOD
003 Cefuroxime 27 N N N N N P N NR NR NR <LOD <LOD <LOD <LOD <LOD
004 Augmentin 14 N N N P P N NR NR NR NR <LOD <LOD 0.16 <LOD <LOD
005 Augmentin 7,686 N N N P P N N NR NR NR <LOD 0.02 0.13 0.03 <LOD
006 Cefuroxime 4 N N N N N N NR NR NR NR 0.03 <LOD 0.16 0.64 <LOD
007 Augmentin 146 N N P P P N N NR N NR <LOD <LOD <LOD <LOD <LOD
008 Amoxicillin 95 N N N N P N NR NR NR NR <LOD <LOD 0.04 <LOD <LOD
009 Ceftriaxone 401 N N N N N N P NR NR NR <LOD <LOD 0.06 0.04 <LOD
010 Augmentin 300 N N N P P N N NR N NR <LOD 0.02 0.03 0.02 <LOD
011 Augmentin 36 NR NR NR NR NR N N NR N NR 0.02 0.04 0.11 0.03 <LOD
012 Augmentin 30 N N N NR P N N NR NR NR <LOD <LOD <LOD 1.91 <LOD
013 Augmentin 124 N N N N N N NR NR NR NR 0.02 0.01 0.02 0.05 0,05
014 Cefuroxime 1,847 N N N N P NR NR NR N NR 2.80 <LOD 0.01 0.01 <LOD
015 Amoxicillin 206 N N N N P N NR NR NR NR 0.01 <LOD <LOD <LOD <LOD
016 Amoxicillin 152 P N N N N N NR NR NR NR <LOD <LOD <LOD 0.49 <LOD
017 Amoxicillin 114 N N N N P N NR NR NR NR <LOD <LOD <LOD 0.35 <LOD
018 Augmentin 42 N N N N P N NR NR NR NR 0.01 <LOD 0.02 0.16 <LOD
019 Augmentin 126 N N N P P N NR NR NR NR 0.01 <LOD 0.01 0.14 <LOD
020 Amoxicillin 353 N N N N P N NR NR NR NR <LOD <LOD 0.02 0.07 <LOD
021 Augmentin 287 N N N P P N N NR NR NR 0.01 <LOD 0.01 <LOD <LOD
022 Amoxicillin 273 N N N N N N N NR N N <LOD <LOD 0.02 0.03 <LOD
023 Benzylpenicillin 286 P P N P N N N N NR NR <LOD <LOD <LOD <LOD <LOD
024 Augmentin 228 NR NR P NR NR NR N NR NR NR <LOD <LOD <LOD <LOD <LOD
025 Ceftriaxone 8 N N N N N N P N NR NR <LOD <LOD <LOD <LOD <LOD
026 Augmentin 187 N N N N N N NR NR NR NR <LOD <LOD <LOD 0.04 <LOD
027 Amoxicillin 135 N N N N N N NR NR NR P 0.01 0.01 0.07 0.02 <LOD
028 Augmentin 434 NR NR NR NR NR N N NR P NR 0.01 <LOD <LOD 0.02 <LOD
029 Augmentin 130 N N N N P N N NR NR NR <LOD <LOD 0.01 <LOD <LOD
030 Augmentin 267 N N P NR P N N NR NR NR <LOD <LOD <LOD <LOD <LOD
031 Augmentin 241 N N N N P N N NR NR NR <LOD <LOD <LOD <LOD <LOD
032 Cefuroxime 245 N N N N N P NR NR NR NR <LOD <LOD <LOD <LOD <LOD
033 Cefuroxime 9 N N N N N N NR NR NR NR <LOD <LOD 0.03 0.05 <LOD
034 Cefuroxime 47 N N N N N P P P NR NR 0.08 <LOD <LOD <LOD <LOD
035 Augmentin 348 N N N N N N NR NR NR NR <LOD <LOD <LOD <LOD <LOD
036 Cefuroxime 177 N N N N N P N NR NR NR <LOD <LOD <LOD <LOD <LOD
037 Cefuroxime 457 N N N N N P P NR N NR 0.08 <LOD 0.04 <LOD <LOD
Controls – – – – – – – <LOD <LOD <LOD <LOD <LOD
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Regarding the culprit drug that caused the allergic reaction, for CFR only five patients tested positive by prick 
tests, two were negative and two were not tested (see Table 2). The H1 CFR -llanyl determinant detected five 
patients diagnosed as positive for CFR with values ranging from 0.03 to 2.80 IU/mL. Interestingly, this antigen 
detected patient 006 that tested negative by prick tests. The IgE values for CFR were 0.37 and 2.80 IU/mL for 
patients 002 and 014, respectively. Fortunately, no cross-reactivity was observed for patient 014 to CFR, CFO, 
CFT, MRP or AZT. However, patient 002 was tested positive by skin tests for CFT and MRP. As the results of 
the skin tests and BLC-specific IgE quantifications differed, special attention was paid to these patients owing 
to the high health risk for CFR administration and the possibility of cross-reactivity. With patients 009 and 025, 
for whom CFT provoked an allergic reaction, our determinant was not selective enough to detect it, but both 
patients were skin-tested positive.
To CFO, MRP and AZT, none of the studied patients had an allergic episode. Of the 17 patient samples with 
specific IgE values to MRP, four had specific IgE values above 0.35 IU/mL (patients 006, 012, 016 and 017) and 
two between 0.10 and 0.20 IU/mL (patients 018 and 019). With CFO, of the 15 positive patients detected, four 
had specific IgE values between 0.10 and 0.20 IU/mL (patients 004, 005, 006 and 011). It is emphasised that none 
of these patients was skin-tested for MRP nor CFO. This fact could have potential effects because patients can 
be affected by them or be at-risk for anaphylaxis.
The purpose of our study was to produce a panel of major and minor determinants for CFR, CFO, CFT, 
MRP and AZT to develop a multiplex in vitro assay to detect specific IgE for these BLCs. We not only produced 
a panel of determinants, but also worked on developing a panel of possible epitopes using different carrier pro-
teins. Firstly, our results with patients showed that no major (-lloyl) determinants were detected in any of the 
selected subjects, nor in the HSA-based determinants. These results reveal the importance of the conjugation 
route and the selection of the appropriate carrier protein. However, it cannot exclude HSA as a carrier protein 
candidate with immunogenic properties or -lloyl determinants as antigenic determinants to be used in further 
studies as this study followed a specific conjugation methodology. Besides, a good correlation was also found 
between positive in vitro immunoassay responses to CFR and skin test results, which reveals that the produced 
determinant is specific and can be used for in vitro diagnosis, especially if we consider that both assays (spe-
cific IgE quantification and prick test) confirmed five positive patients. Moreover, the multiplex assay with the 
appropriate antigens was able to detect specific IgE values to CFR in one patient with a negative prick-test result 
(patient 006) and in two patients in whom prick tests were not performed (patients 002 and 014). Therefore, IgE 
assays might be suitable when skin tests have not been done, when using non-soluble BLCs, with severe reactions 
or with high-risk patients. In fact, for MRP for which no skin tests were performed, four patients were positive 
according to the specific IgE amount determined with values above 0.35 IU/mL (patients 006, 012, 016 and 017) 
with the meropenem determinant. This confirmed the utility of the multiplexed assay for drug allergy diagnoses.
The use of in vivo and in vitro tests to diagnose allergic patients to BLCs needs to be adapted to the current 
scenario in which the consumption pattern of these antibiotics has changed, and penicillins are being progres-
sively replaced mainly with other antibiotics like cephalosporins, carbapenems, monobactams, quinolones and 
 tetracyclines40. Some authors suggest that skin testing with antigenic determinants of penicillins is no longer suf-
ficient for evaluating patients for BLC allergy and that cross-reactivity between penicillins and  cephalosporins41 
or  carbapenems12 can exist. For instance, cephalosporins with identical R side chains should be avoided for 
patients believed to be selectively allergic to aminopenicillins (e.g. cefatrizine and cefadroxil for amoxicillin or 
cefaclor for ampicillin)42. However, these patients may receive other cephalosporins that can also promote an 
allergic  episode43, which could be avoided by analysing these sera by a multiplex in vitro assay.
In our study, specific IgE levels to CFT and MRP were observed in the patients whose culprit drug was aug-
mentin or AMX. This was the case, for instance, of patients 012, 016 and 017 whose specific MRP IgE values 
ranged from 0.35 to 1.91 IU/mL. Cross-reactivity between CFR and MRP was noted in patient 006 whose cul-
prit drug was CFR and was positive to MRP (IgE = 0.64 IU/mL). Data about related to cross-reactivity between 
cephalosporins and carbapenems is insufficient, but some authors suggest that carbapenems should be considered 
potentially cross-reactive with cephalosporins because of similarities to the β-lactam  ring44. In patient 006, IgE 
antibodies were probably directed against the β-lactam ring, a common nuclear determinant shared by all BLCs, 
but no recognition was observed for CFT. The acetyl and carbamoyl groups of the R′ lateral chain of cefotaxime 
and cefuroxime, respectively, can be easily  hydrolysed45 when producing antigens. However, the thiotriazinedione 
moiety of CFT is stable and may take part in the epitope of the antigen, which was probably the reason for the 
negative response to CFT.
Consequently, it is necessary to use a panel of BLCs because there are no clinically approved validated rea-
gents. A well-established multiplex in vitro method was herein followed to evaluate the presence of IgE antibodies 
in a defined allergic population in which augmentin, CFR and AMX were the drugs that most often induced 
immediate reactions. As some authors suggest that anaphylaxis predominates the cutaneous  condition46 (pre-
sented as urticaria) in allergic reactions to BLCs, using a multiplex in vitro test is a good alternative to in vivo 
assays to detect positive patients in short times and to study a conjunction of BLCs together and instantane-
ously given this multiplex capacity. The problem with false-negatives is also noteworthy. For instance, Demoly 
and Romano indicate a positive provocation test for 8–17% of patients with negative skin tests to  penicillin22. 
Therefore, in those patients who are shown negative by skin and/or drug provocation tests, the combination of 
both in vivo and in vitro tests is a useful approach to detect all the potential allergic patients.
conclusion
The production and evaluation of structural determinants for β-lactam allergy is key for developing sensitive 
and selective in vitro tests to determine specific IgE that can complement in vivo tests, data and clinical his-
tory, whenever possible. The conjunction of both techniques can allow better diagnoses and allow significant 
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delabelling that should allow improvements in future antibiotic treatments of reported BLC allergy. Unlike all 
the studies related to penicillins reactivity, in which the chemical structures of their antigenic determinants are 
already established, the chemistry of other β-lactam antibiotics lacks this information.
Allergic reactions to these families may occur by sensitisation to them or to determinants that share similar 
chemical chains to those of penicillins. Different epitopes have not yet been identified. This study develops a 
multiplex sensitive immunoassay for the in vitro determination of both specific IgG and IgE levels by using major 
and minor determinants of a wide variety of less-studied β-lactam antibiotics, such as cefuroxime, cefotaxime, 
ceftriaxone, meropenem and aztreonam. It demonstrates that all the produced antigenic determinants are selec-
tive for detecting specific anti-β-lactam IgG in rabbit sera, but only minor determinants are able to detect specific 
anti-β-lactam IgE in human serum samples from allergic patients because the -lloyl determinants formed with 
this protocol are not recognised. This work also demonstrates that the carrier protein plays an important role in 
molecular recognition pattern terms as only the prepared H1-derived determinants were specifically recognised 
using allergic patient samples. Thus in patients with a history of a serious and potentially IgE-mediated reaction 
to a cephalosporin, it is critical to avoid re-exposure to the same cephalosporin, a cephalosporin compound 
that shares the same side chain, and even to other BLC sharing the same side chain, such as ceftazidime and 
cefadroxil and aztreonam.
These findings reveal that haptenisation of β-lactam antibiotics renders enhanced and interesting molecular 
recognition events, even when the β-lactam ring remains unmodified. This contribution may improve the cur-
rent clinical diagnostics of allergies to antibiotics cephalosporin, carbapenem and monobactam together with 
drug provocation tests used as the gold standard. Indeed, future studies are needed to corroborate these in vitro 
findings with oral provocation tests.
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